• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Brexpiprazole Ineffective in Mania

Brexpiprazole Ineffective in Mania

September 28, 2021
Richard Moldawsky, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Richard Moldawsky, MD. Dr. Moldawsky has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Vieta E et al, J Psychopharmacol 2021;35(8):971–982


TYPE OF STUDY: Phase III randomized controlled trials


Brexpiprazole is FDA approved in schizophrenia and as an adjunct for major depression and is one of the better-tolerated antipsychotics. Like aripiprazole, it is a partial D2 and 5-HT1A agonist. Unlike most antipsychotics, brexpiprazole has never been studied in acute mania, so these two recently published industry-sponsored trials give us the first glimpse of its antimanic potential.


The trials employed similar designs. Both were large, randomized, placebo-controlled trials that compared brexpiprazole with placebo over three weeks in acute bipolar I mania. The participants were drawn from US and European sites and had a Young Mania Rating Scale (YMRS) score over 24 at entry. Brexpiprazole was started at 2 mg/day and titrated up to 4 mg/day as tolerated. No other medication was allowed except lorazepam on an as-needed basis. The trials enrolled 654 patients, over 75% of whom completed the acute phase.


After three weeks, YMRS scores were about the same for drug and placebo, although the brexpiprazole group scored a little better on the secondary Clinical Global Impression—Bipolar Disorder (CGI-BD) measure.


Both trials included an open-label, long-term phase where symptoms were treated with brexpiprazole for another six months if the investigators thought patients would benefit from continued treatment. Outcome measures over the 26 weeks of this phase showed gradual decreases in YMRS and CGI-BD scores, but the changes were not dramatic and there was no control arm to compare them to.


Brexpiprazole was well tolerated, with akathisia the most commonly reported adverse effect. During the open-label extension, six patients became manic, five became depressed, and four developed suicidal ideation, but these events lacked a placebo arm for comparison.


The multicenter design may have obscured the drug-placebo difference. There are more investigators per patient in multicenter trials, increasing the attention each patient receives and amplifying the placebo effect. However, other antipsychotics have overcome this and yielded positive results in mania during multicenter trials.


The authors conducted a secondary analysis in an attempt to salvage some signal of response in these patients. Based on earlier evidence that poor insight predicts a better response to antipsychotics in mania (Welten CCM et al, J Clin Psychopharmacol 2016;36(1):71–76), they reanalyzed the data and found that poorer insight was associated with a statistically significant improvement on brexpiprazole relative to placebo (odds ratio 2.2, CI 1.1–4.4).


TCPR’s Take
The atypical antipsychotics are a varied class, and we can’t conclude all of them work in acute mania. Stick with those that are FDA approved in mania (aripiprazole, asenapine, cariprazine, olanzapine, quetiapine, risperidone, and ziprasidone), as the others in this class are either untested (eg, lumateperone, lurasidone) or have negative results in this condition (eg, paliperidone).

General Psychiatry
KEYWORDS brexpiprazole mania mood_stabilizers psychopharm-myths psychopharmacology research-update
Richard Moldawsky, MD.

Quetiapine in Bipolar With OCD

More from this author
www.thecarlatreport.com
Issue Date: September 28, 2021
SUBSCRIBE NOW
Table Of Contents
The Schizophrenia-OCD Overlap
Light Therapy: Good for What Ails You?
How to Diagnose ADHD in Bipolar Disorder
Brexpiprazole Ineffective in Mania
Omega-3s and Metabolic Risks in Schizophrenia
CME Post-Test - Mood Disorder, TCPR, October 2021
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.